BLEND LABS INC-A (BLND) Fundamental Analysis & Valuation

NYSE:BLND • US09352U1088

Current stock price

1.46 USD
+0.07 (+5.04%)
At close:
1.48 USD
+0.02 (+1.37%)
After Hours:

This BLND fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. BLND Profitability Analysis

1.1 Basic Checks

  • In the past year BLND was profitable.
  • BLND had a positive operating cash flow in the past year.
  • BLND had negative earnings in each of the past 5 years.
  • BLND had negative operating cash flow in 4 of the past 5 years.
BLND Yearly Net Income VS EBIT VS OCF VS FCFBLND Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 0 -200M -400M -600M

1.2 Ratios

  • The Return On Assets of BLND (-15.22%) is worse than 69.85% of its industry peers.
  • BLND has a worse Return On Equity (-20.06%) than 60.29% of its industry peers.
Industry RankSector Rank
ROA -15.22%
ROE -20.06%
ROIC N/A
ROA(3y)-46.37%
ROA(5y)-66.42%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BLND Yearly ROA, ROE, ROICBLND Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 0 500 -500

1.3 Margins

  • BLND has a Gross Margin of 73.77%. This is in the better half of the industry: BLND outperforms 62.50% of its industry peers.
  • BLND's Gross Margin has improved in the last couple of years.
  • BLND does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 73.77%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y24.6%
GM growth 5Y2.79%
BLND Yearly Profit, Operating, Gross MarginsBLND Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025 0 -100 -200 -300

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. BLND Health Analysis

2.1 Basic Checks

  • BLND does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for BLND has been increased compared to 1 year ago.
  • Compared to 5 years ago, BLND has more shares outstanding
  • BLND has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BLND Yearly Shares OutstandingBLND Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M
BLND Yearly Total Debt VS Total AssetsBLND Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.2 Solvency

  • BLND has an Altman-Z score of -5.23. This is a bad value and indicates that BLND is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -5.23, BLND is doing worse than 84.56% of the companies in the same industry.
  • There is no outstanding debt for BLND. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -5.23
ROIC/WACCN/A
WACC10.83%
BLND Yearly LT Debt VS Equity VS FCFBLND Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 2025 0 200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 2.48 indicates that BLND has no problem at all paying its short term obligations.
  • With a decent Current ratio value of 2.48, BLND is doing good in the industry, outperforming 67.28% of the companies in the same industry.
  • BLND has a Quick Ratio of 2.48. This indicates that BLND is financially healthy and has no problem in meeting its short term obligations.
  • BLND's Quick ratio of 2.48 is fine compared to the rest of the industry. BLND outperforms 68.01% of its industry peers.
Industry RankSector Rank
Current Ratio 2.48
Quick Ratio 2.48
BLND Yearly Current Assets VS Current LiabilitesBLND Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. BLND Growth Analysis

3.1 Past

  • BLND shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 112.50%, which is quite impressive.
  • BLND shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -23.72%.
  • The Revenue has been growing slightly by 5.18% on average over the past years.
EPS 1Y (TTM)112.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-22.13%
Revenue 1Y (TTM)-23.72%
Revenue growth 3Y-19.31%
Revenue growth 5Y5.18%
Sales Q2Q%-21.83%

3.2 Future

  • BLND is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 158.83% yearly.
  • Based on estimates for the next years, BLND will show a quite strong growth in Revenue. The Revenue will grow by 13.23% on average per year.
EPS Next Y662.96%
EPS Next 2Y253.63%
EPS Next 3Y158.83%
EPS Next 5YN/A
Revenue Next Year11%
Revenue Next 2Y12.49%
Revenue Next 3Y13.23%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
BLND Yearly Revenue VS EstimatesBLND Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 100M 200M 300M
BLND Yearly EPS VS EstimatesBLND Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 0 -0.2 -0.4 -0.6

More info and screens

Find the best growth stocksShow best growing peers

3

4. BLND Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 146.00, which means the current valuation is very expensive for BLND.
  • Compared to the rest of the industry, the Price/Earnings ratio of BLND is on the same level as its industry peers.
  • BLND is valuated expensively when we compare the Price/Earnings ratio to 27.42, which is the current average of the S&P500 Index.
  • With a Price/Forward Earnings ratio of 19.14, BLND is valued on the expensive side.
  • Based on the Price/Forward Earnings ratio, BLND is valued a bit cheaper than 64.34% of the companies in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 22.29. BLND is around the same levels.
Industry RankSector Rank
PE 146
Fwd PE 19.14
BLND Price Earnings VS Forward Price EarningsBLND Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 50 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BLND Per share dataBLND EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 0.2 0.3 0.4 0.5

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • BLND's earnings are expected to grow with 158.83% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.22
PEG (5Y)N/A
EPS Next 2Y253.63%
EPS Next 3Y158.83%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BLND Dividend Analysis

5.1 Amount

  • No dividends for BLND!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BLND Fundamentals: All Metrics, Ratios and Statistics

BLEND LABS INC-A

NYSE:BLND (4/24/2026, 8:23:26 PM)

After market: 1.48 +0.02 (+1.37%)

1.46

+0.07 (+5.04%)

Chartmill FA Rating
GICS IndustryGroupSoftware & Services
GICS IndustrySoftware
Earnings (Last)03-10
Earnings (Next)05-07
Inst Owners78.66%
Inst Owner Change3.8%
Ins Owners3.63%
Ins Owner Change5.45%
Market Cap375.38M
Revenue(TTM)123.58M
Net Income(TTM)-25.89M
Analysts80
Price Target4.18 (186.3%)
Short Float %6.15%
Short Ratio3.33
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-100%
Min EPS beat(2)-100%
Max EPS beat(2)-100%
EPS beat(4)1
Avg EPS beat(4)-19.36%
Min EPS beat(4)-100%
Max EPS beat(4)222.55%
EPS beat(8)4
Avg EPS beat(8)-0.28%
EPS beat(12)7
Avg EPS beat(12)4.17%
EPS beat(16)9
Avg EPS beat(16)1.12%
Revenue beat(2)0
Avg Revenue beat(2)-0.95%
Min Revenue beat(2)-1.77%
Max Revenue beat(2)-0.14%
Revenue beat(4)0
Avg Revenue beat(4)-8.95%
Min Revenue beat(4)-30.67%
Max Revenue beat(4)-0.14%
Revenue beat(8)2
Avg Revenue beat(8)-3.88%
Revenue beat(12)4
Avg Revenue beat(12)-1.7%
Revenue beat(16)7
Avg Revenue beat(16)-0.08%
PT rev (1m)-2.61%
PT rev (3m)-2.61%
EPS NQ rev (1m)86.96%
EPS NQ rev (3m)7.5%
EPS NY rev (1m)-3.7%
EPS NY rev (3m)-3.7%
Revenue NQ rev (1m)0.17%
Revenue NQ rev (3m)-6.19%
Revenue NY rev (1m)-3.66%
Revenue NY rev (3m)-7.36%
Valuation
Industry RankSector Rank
PE 146
Fwd PE 19.14
P/S 3.04
P/FCF N/A
P/OCF 32.61
P/B 2.91
P/tB 2.91
EV/EBITDA N/A
EPS(TTM)0.01
EY0.68%
EPS(NY)0.08
Fwd EY5.23%
FCF(TTM)0
FCFYN/A
OCF(TTM)0.04
OCFY3.07%
SpS0.48
BVpS0.5
TBVpS0.5
PEG (NY)0.22
PEG (5Y)N/A
Graham Number0.336019 (-76.98%)
Profitability
Industry RankSector Rank
ROA -15.22%
ROE -20.06%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 73.77%
FCFM N/A
ROA(3y)-46.37%
ROA(5y)-66.42%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y24.6%
GM growth 5Y2.79%
F-Score6
Asset Turnover0.73
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 352.59%
Cap/Sales 9.38%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.48
Quick Ratio 2.48
Altman-Z -5.23
F-Score6
WACC10.83%
ROIC/WACCN/A
Cap/Depr(3y)268.82%
Cap/Depr(5y)168.4%
Cap/Sales(3y)6.14%
Cap/Sales(5y)4.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)112.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-22.13%
EPS Next Y662.96%
EPS Next 2Y253.63%
EPS Next 3Y158.83%
EPS Next 5YN/A
Revenue 1Y (TTM)-23.72%
Revenue growth 3Y-19.31%
Revenue growth 5Y5.18%
Sales Q2Q%-21.83%
Revenue Next Year11%
Revenue Next 2Y12.49%
Revenue Next 3Y13.23%
Revenue Next 5YN/A
EBIT growth 1Y50.5%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year73.64%
EBIT Next 3Y45.87%
EBIT Next 5YN/A
FCF growth 1Y99.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y188.26%
OCF growth 3YN/A
OCF growth 5YN/A

BLEND LABS INC-A / BLND Fundamental Analysis FAQ

What is the fundamental rating for BLND stock?

ChartMill assigns a fundamental rating of 4 / 10 to BLND.


What is the valuation status of BLEND LABS INC-A (BLND) stock?

ChartMill assigns a valuation rating of 3 / 10 to BLEND LABS INC-A (BLND). This can be considered as Overvalued.


Can you provide the profitability details for BLEND LABS INC-A?

BLEND LABS INC-A (BLND) has a profitability rating of 2 / 10.


What is the financial health of BLEND LABS INC-A (BLND) stock?

The financial health rating of BLEND LABS INC-A (BLND) is 6 / 10.


Can you provide the expected EPS growth for BLND stock?

The Earnings per Share (EPS) of BLEND LABS INC-A (BLND) is expected to grow by 662.96% in the next year.